Immunai Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
160
- Latest Deal Type
-
2ndary - Private
- Investors
-
20
Immunai General Information
Description
Developer of a bioinformatics platform designed to enhance our ability to understand complex diseases and develop targeted therapies effectively. The company's platform utilises artificial intelligence to analyse large-scale biological datasets and predict treatment outcomes, enabling healthcare researchers to optimise drug discovery and development processes.
Contact Information
Website
www.immunai.comCorporate Office
- 430 East 29th Street
- New York, NY 10016
- United States
Corporate Office
- 430 East 29th Street
- New York, NY 10016
- United States
Immunai Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 9. Early Stage VC (Series B) | 27-Oct-2021 | Completed | Generating Revenue | |||
| 8. Early Stage VC (Series A) | 11-Feb-2021 | Completed | Generating Revenue | |||
| 7. Accelerator/Incubator | 04-Nov-2020 | Completed | Generating Revenue | |||
| 6. Accelerator/Incubator | 10-Jun-2020 | Completed | Generating Revenue | |||
| 5. Seed Round | 14-May-2020 | Completed | Generating Revenue | |||
| 4. Angel (individual) | 25-Dec-2019 | Completed | Generating Revenue | |||
| 3. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 2. Accelerator/Incubator | 01-Nov-2019 | Completed | Generating Revenue | |||
| 1. Accelerator/Incubator | 18-Oct-2019 | Completed | Generating Revenue |
Immunai Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C-2 | ||||||||
| Series C-1 | ||||||||
| Series B-2 | ||||||||
| Series B-1 | ||||||||
| Series A | ||||||||
| Seed-2 | 672,817 | $0.000100 | $7.88 | $7.88 | 1x | $7.88 | 11.4% | |
| Seed-1 | 36,390 | $0.000100 | $5.91 | $5.91 | 1x | $5.91 | 0.62% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Immunai Comparisons
Industry
Financing
Details
Immunai Competitors (2)
One of Immunai’s 2 competitors is Egenesis, a Venture Capital-Backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Egenesis | Venture Capital-Backed | Cambridge, MA | ||||
| Geneious | Formerly PE-Backed | Auckland, New Zealand |
Immunai Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Immunai Patents
Immunai Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026050749-A1 | Compositions and methods comprising fusion polypeptides for use in treating cancer | Pending | 30-Aug-2024 | ||
| WO-2024206738-A1 | Humanized anti-trem2 antibodies | Inactive | 31-Mar-2023 | ||
| US-20240249839-A1 | Systems, software, and methods for multiomic single cell classification and prediction and longitudinal trajectory analysis | Pending | 24-Jan-2023 | ||
| WO-2021035023-A1 | A system for predicting treatment outcomes based upon genetic imputation | Inactive | 20-Aug-2019 | ||
| US-11437148-B2 | System for predicting treatment outcomes based upon genetic imputation | Active | 20-Aug-2019 | G16H50/50 |
Immunai Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Immunai Investors (20)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 8VC | Venture Capital | Minority | ||
| Alexandria Venture Investments | Venture Capital | Minority | ||
| Koch Disruptive Technologies | Venture Capital | Minority | ||
| Piedmont Capital Investments | Venture Capital | Minority | ||
| Catalio Capital Management | Venture Capital | Minority |
Immunai Acquisitions (2)
Immunai’s most recent deal was a Merger/Acquisition with Nebion. The deal was made on 29-Jul-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Nebion | 29-Jul-2021 | Merger/Acquisition | Other Healthcare Technology Systems | ||
| Dropprint Genomics | 25-Mar-2021 | Merger/Acquisition | Biotechnology |
Immunai Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Nebion | Zurich, Switzerland | 2008 |
Immunai FAQs
-
When was Immunai founded?
Immunai was founded in 2018.
-
Where is Immunai headquartered?
Immunai is headquartered in New York, NY.
-
What is the size of Immunai?
Immunai has 160 total employees.
-
What industry is Immunai in?
Immunai’s primary industry is Discovery Tools (Healthcare).
-
Is Immunai a private or public company?
Immunai is a Private company.
-
What is Immunai’s current revenue?
The current revenue for Immunai is .
-
How much funding has Immunai raised over time?
Immunai has raised $295M.
-
Who are Immunai’s investors?
8VC, Alexandria Venture Investments, Koch Disruptive Technologies, Piedmont Capital Investments, and Catalio Capital Management are 5 of 20 investors who have invested in Immunai.
-
Who are Immunai’s competitors?
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
